Compounds studied for effects on cognition, memory, focus and mood, including peptides researched for neuroprotection and stress resilience. Several have approved clinical use only in specific countries, and much of the supporting evidence is preclinical or regional rather than from large international trials. None is an FDA-approved cognitive treatment, and profiles report the evidence stage honestly.
Cognitive compounds are studied for neuroprotection, memory and neuroplasticity. Much of the foundational work comes from Russian and Eastern European research programs and is still being explored elsewhere.
Two of the best-known compounds here share an origin. Semax, an analog of an ACTH fragment, and Selank, based on the immune peptide tuftsin, were both developed at the Institute of Molecular Genetics in Moscow. Semax has been studied for effects on BDNF expression and cerebral circulation; Selank for anxiolytic activity alongside cognitive endpoints. Their evidence base is real, but it is concentrated in a specific national research tradition, with limited large-scale replication in Western trials — a context worth carrying into any claim you read about them.
The category also reaches into neuropeptides such as DSIP (delta sleep-inducing peptide) and broader signalling molecules, since sleep, mood and cognition are deeply linked in the research.
Cognition is genuinely difficult to measure. Memory, attention and mood are multi-dimensional, sensitive to expectation and context, and easy to influence with study design. That is why the bar for a convincing nootropic result is high, and why small open-label studies — common in this category — should be read as preliminary signals rather than conclusions. Route of administration adds another variable: several of these compounds are studied intranasally, and a nasal result does not automatically transfer to other routes.
Semax and Selank are the defining pair and are frequently compared directly; DSIP connects the category to sleep research. Our Semax and Selank article covers the Russian research program and what has — and has not — been replicated.
Synthetic analog of the immunomodulatory peptide tuftsin, developed in Russia and studied for anxiolytic and immune-regulating activity.
Synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone, developed in Russia and studied for nootropic and neuroprotective activity.
Delta sleep-inducing peptide, an endogenous neuropeptide studied for its influence on sleep regulation and the stress response.
Endogenous neuropeptide hormone produced in the hypothalamus, studied for roles in social bonding, lactation and reproductive physiology.
Amyloid-beta 1-42, the aggregation-prone peptide fragment of amyloid precursor protein, studied extensively in Alzheimer's disease research.
